Expression of Enhancer of Zeste Homologue 2 (EZH2) and CD49f in breast cancer and its association with clinicopathological features
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The prevalence of EZH2 and CD49f in breast carcinoma
研究概览
简要总结
Breast cancer is one of the most common tumor in women worldwide, with an estimated number of 2.3 million new cases globally. It is one of the leading causes of female mortality worldwide. To improve the prognosis and outcome of the disease, it is imperative to explore the comprehensive molecular mechanism underlying breast cancer.
This study is a cross sectional observation study on expression of Enhancer of zeste homolog 2 (EZH2) and CD49f in breast cancer and its association with clinicopathological features, that will be conducted in Department of Pathology, Maulana Azad Medical College, New Delhi, India. The primary outcome measures the prevalence of EZH2 and CD49f in breast carcinoma. The secondary outcome will be association of EZH2 and CD49f with clinicopathological features, Estrogen receptor, Progesterone receptor, Her2neu and Ki67 status
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- Female
入选标准
- •Newly diagnosed female patients of breast carcinoma whose biopsy specimens are received in Department of Pathology, MAMC.
排除标准
- •Patients with prior neoadjuvant chemotherapy and/or radiation therapy.
结局指标
主要结局
The prevalence of EZH2 and CD49f in breast carcinoma
时间窗: Baseline
次要结局
- 1) The association of EZH2 and CD49f with clinicopathological features of breast carcinoma like clinical stage, histological grade, tumor size and Tumor Infiltrating Lymphocytes(TILs)
研究者
Dr Vandana Thakur
Maulana Azad Medical College